PepGen Inc.

NasdaqGS PEPG

PepGen Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -82.77 M

PepGen Inc. Free Cash Flow is USD -82.77 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -24.52% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

PepGen Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -66.48 M, a -21.59% change year over year.
PepGen Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -54.67 M, a -220.64% change year over year.
PepGen Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -17.05 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGS: PEPG

PepGen Inc.

CEO	Dr. James G. McArthur Ph.D.
IPO Date	May 6, 2022
Location	United States
Headquarters	245 Main Street
Employees	76
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years